ArticleKidney medicine
Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan.
Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Pooled it
- Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.Clinical and experimental nephrology · 2025Trial
- Development of a nomogram for predicting hyperkalemia in advanced chronic kidney disease.Renal failure · 2026Article
- Clinical impact of an EHR-integrated hyperkalemia management system: a real-world study of 10,934 episodes.Renal failure · 2026Article
- Clinical Outcomes of Hospitalization for Severe Hyperkalemia in the Absence of Life-threatening Manifestations.JMA journal · 2026Article
- Epidemiology of hyperkalemia among US emergency department patients without end-stage renal disease from 2016 to 2024.Clinical and experimental emergency medicine · 2026Article
- [Acute disorders of potassium homeostasis : Diagnosis and emergency treatment].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026Review
- Urgent initiation of hemodialysis versus peritoneal dialysis in severe hyperkalemia: a prospective study.Clinical kidney journal · 2025Article
- Pathophysiology and causes of hyperkalemia: unraveling causes beyond kidney dysfunction.Clinical and experimental nephrology · 2025Review
- The burden of hyperkalaemia in chronic kidney disease: a systematic literature review.Clinical kidney journal · 2025Article
- Economic burden of recurrent hyperkalemia in patients with chronic kidney disease.Journal of managed care & specialty pharmacy · 2024Observational
- Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.International journal of nephrology and renovascular disease · 2024Article
- Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease.Clinical kidney journal · 2023Article
- Long-term outcomes of add-on direct renin inhibition in igA nephropathy: a propensity score-matched cohort study.Journal of nephrology · 2023Article
- Hyperkalemia: Prevalence, Predictors and Emerging Treatments.Cardiology and therapy · 2023Review
- Validation of a new instrument for measuring disease-specific quality of life: A pilot study among patients with chronic kidney disease and hyperkalemia.Annals of clinical epidemiology · 2023Article
- A New Perspective to Longstanding Challenges with Outpatient Hyperkalemia: A Narrative Review.Canadian journal of kidney health and disease · 2023Review
- Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease.Frontiers in medicine · 2023Article
- Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study.Frontiers in physiology · 2023Article
- Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults.Clinical pharmacology in drug development · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE &
objectiveHyperkalemia is a common electrolyte abnormality of chronic kidney disease and heart failure associated with increased mortality and morbidity. We aimed to assess the long-term economic burden of hyperkalemia.
designObservational cohort study using a Japanese nationwide hospital claims database (April 1, 2008, to September 30, 2018). SETTING & POPULATION: : Patients 18 years or older with at least 1 serum potassium value (N = 1,208,894). EXPOSURES: Hyperkalemia defined with the presence of at least 2 serum potassium values ≥ 5.1 mmol/L. OUTCOME MEASURES: Direct health care costs and resource use in patients with hyperkalemia within and after 12 months from first hyperkalemia episodes. ANALYTICAL APPROACH: Health care costs and resource use were compared with propensity score-matched or nonmatched normokalemic controls. Multivariable regression analysis was performed to examine factors associated with health care costs.
results27,534 patients with hyperkalemia and 233,098 normokalemic controls were studied. Mean ± SD age was 73±13 years in patients with hyperkalemia; among them, 59% and 35% had chronic kidney disease and heart failure, respectively. In the propensity score-matched cohort (n = 5,859 in each group), average numbers of hospitalizations per patient per year in patients with hyperkalemia within and after 12 months were 1.2 and 1.6 times higher, respectively, compared with those in patients with normokalemia. The total cost per patient in patients with hyperkalemia was higher than for controls, with mean differences of $8,611 (95% CI, $8,046-$9,175) within 12 months and $5,150 (95% CI, $4,733-$5,566) after 12 months. The number of repeat hyperkalemic episodes was the factor with the strongest association with long-term health care costs, whereas severity of hyperkalemia was not associated. LIMITATIONS: This study used secondary data; therefore, residual confounders may not be fully excluded.
conclusionsHyperkalemia was associated with significant long-term economic burden with frequent hospitalizations due to recurrent episodes, indicating the importance of hyperkalemia treatment for the sake of reducing health economic burdens and clinical complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.